X
Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    Concerns Rise Over Shortage of Medical Products In The USA

    Key Areas For AI/ML Drug Development – FDA Discussion Paper

    Mettler-Toledo Launches X2 Series of X-ray Solutions to Bring Enhanced Product Safety to a Wider Audience

    Mettler-Toledo Launches X2 Series of X-ray Solutions to Bring Enhanced Product Safety to a Wider Audience

    Rising Pharmaceuticals Demand Drives Tablet Coatings Market

    Chinas Institute of Materia Medica Partners With Cyclica on Innovative Drug Repurposing for COVID-19

    Particle Size Distribution Real-Time Monitoring With PEACE

    Mettler-Toledo Showcases a Suite of Affordable Smart Inspection Technologies at Interpack to Boost Pharma Productivity

    Mettler-Toledo Showcases a Suite of Affordable Smart Inspection Technologies at Interpack to Boost Pharma Productivity

    Recipharm supports FDA approval of Perrigos AB-rated generic product

    FDA approves the manufacture of new microbiome-based therapeutic VOWSTTM at Recipharm site

    authorisation for roxadustat in China

    ABPI and NHS Are in Talks for New Medicines Scheme in the UK

    New Approach To Gene Editing For Improved Cancer Treatment

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    Concerns Rise Over Shortage of Medical Products In The USA

    Key Areas For AI/ML Drug Development – FDA Discussion Paper

    Mettler-Toledo Launches X2 Series of X-ray Solutions to Bring Enhanced Product Safety to a Wider Audience

    Mettler-Toledo Launches X2 Series of X-ray Solutions to Bring Enhanced Product Safety to a Wider Audience

    Rising Pharmaceuticals Demand Drives Tablet Coatings Market

    Chinas Institute of Materia Medica Partners With Cyclica on Innovative Drug Repurposing for COVID-19

    Particle Size Distribution Real-Time Monitoring With PEACE

    Mettler-Toledo Showcases a Suite of Affordable Smart Inspection Technologies at Interpack to Boost Pharma Productivity

    Mettler-Toledo Showcases a Suite of Affordable Smart Inspection Technologies at Interpack to Boost Pharma Productivity

    Recipharm supports FDA approval of Perrigos AB-rated generic product

    FDA approves the manufacture of new microbiome-based therapeutic VOWSTTM at Recipharm site

    authorisation for roxadustat in China

    ABPI and NHS Are in Talks for New Medicines Scheme in the UK

    New Approach To Gene Editing For Improved Cancer Treatment

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home News

Impact of Global Events On The Biopharmaceutical Industry

Content Team by Content Team
23rd May 2023
in News

Lower valuations can benefit acquirers in 2023, but IPOs and venture funding are expected to be slow. To address valuation challenges, the biopharma sector must prioritize clinical successes this year, particularly in areas such as respiratory syncytial virus, Alzheimer’s disease, and cancer. Offering crucial guidance for company managers, investors, and industry professionals, a recent analysis presents valuable insights and the essential information to successfully navigate the intricate healthcare and biopharma sectors.

In the pharmaceutical market of 2023, monoclonal antibodies (mAbs) and vaccines, led by Merck Sharpe & Dohme’s Keytruda, a mAb cancer treatment, are expected to dominate. The impact of Covid-19 on the industry remains uncertain. Ozempic, a medication for diabetes, is expected to experience significant sales growth, but the recent launch of Lilly’s Mounjaro is facing challenges due to supply issues. Pfizer’s Comirnaty and Paxlovid are anticipated to maintain the top position in prescription drug sales, surpassing Keytruda. Novo Nordisk and Lilly are experiencing growth in their diabetes and obesity agents. Daiichi Sankyo, CSL, and Grifols, among other smaller companies, are anticipated to have a notable influence in the industry. AstraZeneca’s ranking is boosted by its success in oncology and the acquisition of Alexion with its fast-growing Ultomiris, a mAb autoimmune treatment.

Alzheimer’s disease will be a focus in biopharma in 2023 as Eisai and Lilly race to bring their antibodies to the market. Uncertainties remain regarding FDA approvals and reimbursement for Lilly’s Donanemab. Gene therapies like Duchenne from Sarepta and Roche face uncertainty in predicting demand and securing reimbursement. Opportunities exist in respiratory syncytial virus vaccines, with GSK and Pfizer leading the way. It is also important to closely monitor the advancements in Apellis’s treatment for geographic atrophy. Daiichi Sankyo’s two highly anticipated novel antibody-drug conjugates, Datopotamab deruxtecan and Talquetamab, hold promise, along with Karuna’s schizophrenia and Alzheimer’s treatment KarXT. The FDA’s green light for clinical trials of Intellia and Regeneron’s NTLA-2001 is still awaited, while Roche and MSD’s mAb triagolumab remains of interest in 2023.

A rebound in novel drug approvals in 2023, following the dip in 2022 has been predicted by an analysis. This suggests that the recent FDA approval slowdown may be temporary. Stricter accelerated approvals are expected, similar to those seen in 2022. Smaller pharmaceutical companies may face challenges as confirmatory phase 3 trials need to be in progress before accelerated approval can be considered. Changes to the approval pathway have developed, but advocates may push for further reforms in the coming months.

Anticipated factors such as the conflict in Ukraine, escalating global interest rates, and apprehensions regarding drug price reform in the US are projected to impact the industry. The impact of the Inflation Reduction Act (IRA) on biotech versus small-molecule investments remains uncertain due to the discordant government resulting from the mid-term elections. Cash conservation efforts, portfolio prioritization, job cuts, and deals driven by fear may affect many, especially smaller companies. Analysts have mixed opinions on the US biotech market, with some believing it has hit its bottom while others anticipate further declines throughout 2023. The IPO market for biotech saw a downturn in 2022, and its recovery in 2023 remains uncertain. The venture capital world will also face challenges due to the ongoing biotech bear market, impacting private financing and exit struggles.

The biopharma M&A landscape in 2022 did not meet expectations, but Horizon Therapeutics has attracted initial interest from major players. The valuation of Horizon could make it the largest biopharma deal since AstraZeneca’s acquisition of Alexion. Biogen, Horizon, and Vertex are considered desirable targets for this year. Funding difficulties, regulatory uncertainties, and market fluctuations are expected to persist in the biopharma industry in 2023. To prosper in the upcoming year, companies must adeptly navigate these challenges, and vigilantly monitor the evolving landscape placing emphasis on clinical achievements.

Previous Post

Pharmaceutical Setups To Adopt Supply Chain Digitalization

Next Post

Concerns Rise Over Shortage of Medical Products In The USA

Related Posts

Drug Development

Concerns Rise Over Shortage of Medical Products In The USA

23rd May 2023
Pharmaceutical Setups To Adopt Supply Chain Digitalization
News

Pharmaceutical Setups To Adopt Supply Chain Digitalization

20th May 2023
Catalent Invests $14 Million At Its Eberbach, Germany Softgel Facility
Facilities & Operation

Transparency In Global Pharma Supply Chains To Tackle Fraud

20th May 2023
Facilities & Operation

Temperature Control In Pharmaceutical Cold Chain – Key Areas

19th May 2023
Manufacturing

Pharma Adopts Digitalization For Improved Drug Manufacturing

19th May 2023
IPR Data Management

Role of Blockchain In Pharmaceutical Supply Chain Efficiency

18th May 2023
Next Post

Concerns Rise Over Shortage of Medical Products In The USA

Latest News

Drug Development

Concerns Rise Over Shortage of Medical Products In The USA

23rd May 2023
News

Impact of Global Events On The Biopharmaceutical Industry

23rd May 2023
Pharmaceutical Setups To Adopt Supply Chain Digitalization
News

Pharmaceutical Setups To Adopt Supply Chain Digitalization

20th May 2023
Catalent Invests $14 Million At Its Eberbach, Germany Softgel Facility
Facilities & Operation

Transparency In Global Pharma Supply Chains To Tackle Fraud

20th May 2023
Facilities & Operation

Temperature Control In Pharmaceutical Cold Chain – Key Areas

19th May 2023
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack

System

  • Search
  • Sitemap
  • RSS Feed

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In